CareDx (CDNA) Q2 2025 Earnings Transcript

CareDx reported Q2 adjusted revenue of $90.5 million, up 14%, with adjusted EBITDA improving to $9.1 million from a $0.3 million loss and non-GAAP gross margin rising 340 bps to 70.4%. The company narrowed 2025 revenue guidance to $367 million-$373 million while reaffirming $29 million-$33 million adjusted EBITDA, but flagged potential Medicare LCD headwinds of about $15 million to $30 million annually depending on final policy. Operationally, it launched AlloSure Plus, expanded payer coverage by 4.2 million lives, generated $10 million in operating cash flow, and announced CFO Abhishek Jain's retirement and Nathan Smith as successor.

Analysis

CDNA is moving from a pure reimbursement beta story toward a platform execution story: the incremental value now comes less from a single assay and more from workflow lock-in, payer penetration, and data-driven bundling. EPIC connectivity matters because it lowers ordering friction at the point of care, which should disproportionately convert surveillance protocols in large transplant centers; that creates a compounding effect where better utilization improves both test economics and evidence generation. The second-order winner is the company's own install base, while competitors with weaker EHR integration or narrower evidence packages will struggle to defend share once ordering becomes embedded in the clinical workflow.

The market is likely underestimating how much of the near-term P&L is now tied to reimbursement mix rather than raw demand. Even the more benign reimbursement scenario creates a meaningful air pocket, but the bigger issue is that the headline guidance midpoint may be preserved while the quality of earnings deteriorates if Medicare policy compresses attach rates or forces product unbundling. That said, management's modeling suggests the operational engine is already offsetting some policy risk through higher ASPs, denials improvement, and collections; this is a multi-quarter offset, not an immediate shield.

The contrarian angle is that the stock may not deserve a simple "regulatory overhang" discount if the draft policy ultimately codifies surveillance coverage and preserves multimodal testing economics. In that case, the current setup becomes a delayed re-rate on evidence + workflow adoption, and the biggest upside surprise could come from heart rather than kidney as protocol adherence rises. The main reversal risk is not demand collapse; it is a final LCD that preserves coverage but structurally caps unit economics more than the market expects, which would push the story from growth to margin-defense for several quarters.

Key Decisions for Investors

• Trade the policy event with a defined-risk structure: buy CDNA Jan-2026 calls and finance with lower-strike call spreads only after the LCD comment period closes; target upside into the final policy decision over the next 2-4 months, with max loss capped to premium.
• If already long CDNA, reduce into strength ahead of the final LCD and re-add on any post-policy selloff if the stock de-rates on headline risk but reimbursement coverage remains intact; that is the highest-probability entry for a 6-12 month re-rating.
• Pair trade: long CDNA / short MYGN for 3-6 months. CDNA has a clearer workflow and reimbursement catalyst path, while MYGN only gets a weak analog sympathy benefit from the CFO overlap and broader diagnostics sentiment.
• For event-driven accounts, hedge CDNA with short-dated puts into the September CLFS pricing window; this isolates the risk that coding/pricing math becomes a second negative leg before LCD finalization.
• If seeking lower-volatility exposure, own CDNA only on a pullback to where the market prices the $30M headwind scenario as base case; risk/reward improves materially if investors over-discount the worst-case reimbursement path.